S. de Witte, Erasmus MC presents MERLIN findings in 2017

S. de Witte of Erasmus University Medical Center in Rotterdam took to the road in 2017 to present MERLIN results at five conferences in Belgium, The Netherlands and Spain:

· Erasmus MC, Science days of the Department of Internal Medicine, Antwerp
Poster: IMPACT OF CULTURE EXPANSION AND INFLAMMATORY CYTOKINE CHALLENGE ON DNA METHYLATION PROFILES IN MSC

· BOOT conference, Dutch Transplantation Society, Groningen
Presentation 1: Ageing of bone marrow and umbilical cord-derived MSC during culture expansion
Presentation 2: In vivo tracking of live and dead mesenchymal stromal cells

· MOLMED day, Erasmus MC molecular medicine, Rotterdam
Poster: IMPACT OF CULTURE EXPANSION AND INFLAMMATORY CYTOKINE CHALLENGE ON DNA METHYLATION PROFILES IN MSC

· European Society for Organ Transplantation (ESOT), Barcelona
Presentation 1: Impact of culture expansion and inflammatory cytokine challenge on DNA methylation profiles in MSC
Presentation 2: Tracking and fate of umbilical cord-derived MSC after intravenous infusion in mice (presented by F. Luk)

· European Hematology Association (EHA), EHA-SWG Scientific Meeting on Shaping the Future of Mesenchymal Stromal Cells Therapy, Amsterdam
Presentation: Immunomodulation by therapeutic mesenchymal stromal cells (MSC) is triggered through phagocytosis of MSC by monocytic cells

After six conference talks and poster presentations, she remarked, ”It was nice to connect with the experts in the field”.

MERLIN will present at EU-MSC2 meeting in Leiden in September

Hosted by Leiden University Medical Center, the EU MSC2 2017 meeting in Leiden, NL on September 12th and 13th will assemble twelve EU-funded, mesenchymal stromal cell-focussed consortia. Projects to be presented include: REDDSTARREACHRETHRIM, Stellar, MERLINNephstromSCIENCEVISICORT and Adipoa-2AUTOSTEMBOOSTB4, SEPCELL, RESSTORE, and RESPINE. This two day, interactive meeting will be held at the Stadsgehoorzaal Leiden. Three overarching aspects of the EU-MSC2 meeting include: mechanisms of action and potency assays; an interactive panel discussion on product development, and product development and market authorisation in a changing regulatory landscape.

The objectives of the meeting are to:

  • Enhance knowledge-sharing between EU research groups working in the mesenchymal stromal cell biology domain
  • Engage with European Commission Project Officers and other stakeholders from International Society of Cellular Therapy, stem cell ethicists and the European Medicines Agency (EMA)
  • Assemble trans-disciplinary research groups working across the global health spectrum but with a common focus of mesenchymal stromal cell biology
  • Bring up-and-coming researchers together for networking purposes, and to explore future consortium building and international funding application opportunities

Expected impacts and outcomes:

  • Provide opportunities to develop new mesenchymal stromal cell networks
  • Disseminate the findings and challenges between MSC-focussed consortia
  • Improve the communication potential of research, outcomes and the value of the research
  • Explore potential for new commercial technologies
  • Collectively enhance the quality and impact of planned clinical trials

These EU-funded projects are:

  • Improving the quality of life for European citizens
  • Progressing the clinical translation of MSC research and developments

For more information, please visit EU MSC2 2017.
Register via Eventbrite by August 14 2017.
Read the EU-MSC2 2015 meeting report here.

Proteomic analysis of the secretome of human bone marrow-derived MSCs

MERLIN team at the Universitá degli Studi di Padova publish “Proteomic analysis of the secretome of human bone marrow-derived mesenchymal stem cells primed by pro-inflammatory cytokines” in the Journal of Proteomics, 21July 2017

Congratulations to all authors: Elisa Maffioli, Simona Nonnis, Roberta Angioni, Fabiana Santagata, Bianca Calí, Lucia Zanotti, Armando Negri, Antonella Viola, Gabriella Tedeschi.

In summary, the secretion of a broad range of bioactive molecules is believed to be the main mechanism by which mesenchymal stem cells (MSC) exert specific therapeutic effects. MSC are very versatile and respond to specific environments by producing and releasing a variety of effector molecules. To the best of our knowledge this is the first study aimed at describing the secretome of human MSC primed using a mixture of cytokines, to mimic pro-inflammatory conditions encountered in vivo, by a quantitative high-resolution mass spectrometry based approach. The main output of the study concerns the identification of a list of specific proteins involved in inflammation and angiogenesis which are overrepresented in stimulated MSC secretome.
This study found that pro-inflammatory cytokines have a strong impact on the secretome of human bone marrow-derived MSC and that the large majority of cytokine-induced proteins are involved in inflammation and/or angiogenesis.
Overall, these studies represent key steps necessary to characterize the different biology of MSC in the two organisms and design successful pre- clinical experiments as well as clinical trials. The full publication is available at: https://doi.org/10.1016/j.jprot.2017.07.012

Merlin Article Published on Optimisation of MSC

A new Merlin article on Optimisation of MSC has just been published in Stem Cell Research and Therapy. The piece is entitled “Cytokine treatment optimises the immunotherapeutic effects of umbilical cord-derived MSC for treatment of inflammatory liver disease” and was lead by Samantha de Witte from Erasmus MC in the Netherlands. The paper is open access (Stem Cell Research & Therapy 20178:140 DOI: 10.1186/s13287-017-0590-6) and can be downloaded here. 

Congratulations to all the authors (Samantha F. H. de Witte; Ana M. Merino, Marcella Franquesa, Tanja Strini, Johanna A. A. van Zoggel, Sander S. Korevaar, Franka Luk, Madhu Gargesha, Lisa O’Flynn, Debashish Roy, Steve J. Elliman, Philip N. Newsome, Carla C. Baan and Martin J. Hoogduijn).

Merlin Meet in Rotterdam

The Merlin team had a very successful plenary in Rotterdam on 10 and 11 May. Updates were presented on each WP. MSC production and preparation for the upcoming trial were naturally a key focus at this stage of the project. Publications and plans for future work were also discussed. Many thanks to EMC for hosting and to all the partners for their input into a very productive and enjoyable meeting!

MERLIN article for publication in Cytotherapy

A Merlin paper on the impact of long-term in vitro expansion on MSCs has been accepted for publication in Cytotherapy. The article is entitled “Aging of bone marrow and umbilical cord–derived mesenchymal stromal cells during expansion” (by Samantha de Witte (pictured above), Eleonora E. Lambert, Ana Merino, Tanja Strini, Hannie J.C.W. Douben, Lisa O’Flynn, Steve J. Elliman, Annelies J.E.M.M. de Klein, Philip N. Newsome, Carla C. Baan and Martin J. Hoogduijn). The corrected proof is now available on line: here. Congratulations to the authors!

Merlin Newsletter Autumn 2016

newsletter-autumn-2016

The project team are pleased to issue the first Merlin Newsletter (for Autumn 2016). You can access the newsletter above. Contents in this edition include:

  • MERLIN at a Glance – a reminder of the project’s key aims and objectives.
  • Read All About it – details of some of our recent publications.
  • At the Lectern – some key presentations delivered by the MERLIN team.
  • Progress and Next Steps – where to find progress updates and a look at next steps.
  • Meet the Team – the partners behind the project.

 

 

Merlin Plenary Meeting in Galway

Merlin partner Orbsen hosted the latest Merlin plenary, held in Galway on 17 and 18 October. The meeting was very productive and included updates from all scientific work packages, aswell as reviews of IP, dissemination/exploitation and use of resources. Break-out sessions were also organised so that PIs and postdocs could collaborate in smaller groups. The team looks forward to delivering the work plan agreed for the weeks and months ahead.

Merlin article published in “Leukemia”

An article published by Merlin researchers from UNIPD has recently been published in the “Leukemia” journal. The piece is entitled  “Mouse mesenchymal stem cells inhibit high endothelial cell activation and lymphocyte homing to lymph nodes by releasing TIMP-1(Author(s): Zanotti L, Angioni R, Calì B, Soldani C, Ploia C, Moalli F, Gargesha M, D’Amico G, Elliman S, Tedeschi G, Maffioli E, Negri A, Zacchigna S, Sarukhan A, Stein JV, Viola A) and appears in the May issue. The article deals with the impact of MSC on immunity and inflammation and identifies TIMP-1 as a novel biomarker for MSC-based therapy. You can access the article here.

Merlin Report for Year 2

In March 2015 we issued a report summarising the work undertaken during the first year of the project. Our second report, for year 2 of Merlin is now available. You can access the year 2 report  below.

MERLIN Report Year 2